Aims Genetic association Studies have suggested chat the single nucleotide
polymorphism (SNP) at position 118 of the human mu -opioid receptor (MOR) g
ene could be a potential risk Factor For drug treatment variability in pati
ents. Therefore, we wanted to develop a fast and reliable detection method
for this SNP which is applicable in a clinical setting.
Methods To detect the polymorphism at position A118-->G in the human MOR, g
ene we used the fluorescence resonance energy transfer (FRET)-PCR technique
with subsequent melting curve analysis.
Results The polymorphism at position A118-->G in the human MOR gene could b
e clearly discriminated with melting peak temperatures of 69.8 degrees C an
d 63.8 degrees C, corresponding to the wild type and mutated MOR allele, re
spectively. The results from FRET-PCR were validated by sequencing and rest
riction-fragment length polymorphism (RFLP). Screening of blood samples fro
m 100 subjects showed an allelic distribution for the human MOR alleles of
79% homozygous wild type). 20% (heterozygous) and 0.9% (homozygous mutated)
Conclusions The FRET-PCR protocol for detection of the human MOR gene polym
orphism at position 118 offers a rapid and reliable method which could be u
sed for population screening of this and other genes.